Report Detail
Global Chronic Obstructive Pulmonary Disease Drugs Market Insights, Forecast to 2025
- RnM3447447 |
- 22 May, 2019 |
- Global |
- 119 Pages |
- QYResearch |
- Pharma & Healthcare
Chronic obstructive pulmonary disease ( COPD ) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs.
The inhalers segment dominated the global COPD drugs market
The global Chronic Obstructive Pulmonary Disease Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Chronic Obstructive Pulmonary Disease Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Chronic Obstructive Pulmonary Disease Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Chronic Obstructive Pulmonary Disease Drugs in these regions.
This research report categorizes the global Chronic Obstructive Pulmonary Disease Drugs market by top players/brands, region, type and end user. This report also studies the global Chronic Obstructive Pulmonary Disease Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
AstraZeneca
Boehringer Ingelheim
GSK
Novartis
Teva Pharmaceuticals
Ache Laboratorios Farmaceuticos
Almirall
Aquinox Pharmaceuticals
Ario Pharma
Asmacure
Astellas Pharma
BioMarck Pharmaceuticals
Market size by Product
Inhalers
Nebulizers
Market size by End User
Emphysema
Chronic Bronchitis
Refractory Asthma
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Chronic Obstructive Pulmonary Disease Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Chronic Obstructive Pulmonary Disease Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Chronic Obstructive Pulmonary Disease Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Chronic Obstructive Pulmonary Disease Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Chronic Obstructive Pulmonary Disease Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Chronic Obstructive Pulmonary Disease Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Chronic Obstructive Pulmonary Disease Drugs Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Chronic Obstructive Pulmonary Disease Drugs Market Size Growth Rate by Product
- 1.4.2 Inhalers
- 1.4.3 Nebulizers
- 1.5 Market by End User
- 1.5.1 Global Chronic Obstructive Pulmonary Disease Drugs Market Size Growth Rate by End User
- 1.5.2 Emphysema
- 1.5.3 Chronic Bronchitis
- 1.5.4 Refractory Asthma
- 1.5.5 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Chronic Obstructive Pulmonary Disease Drugs Market Size
- 2.1.1 Global Chronic Obstructive Pulmonary Disease Drugs Revenue 2014-2025
- 2.1.2 Global Chronic Obstructive Pulmonary Disease Drugs Sales 2014-2025
- 2.2 Chronic Obstructive Pulmonary Disease Drugs Growth Rate by Regions
- 2.2.1 Global Chronic Obstructive Pulmonary Disease Drugs Sales by Regions
- 2.2.2 Global Chronic Obstructive Pulmonary Disease Drugs Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Chronic Obstructive Pulmonary Disease Drugs Sales by Manufacturers
- 3.1.1 Chronic Obstructive Pulmonary Disease Drugs Sales by Manufacturers
- 3.1.2 Chronic Obstructive Pulmonary Disease Drugs Sales Market Share by Manufacturers
- 3.1.3 Global Chronic Obstructive Pulmonary Disease Drugs Market Concentration Ratio (CR5 and HHI)
- 3.2 Chronic Obstructive Pulmonary Disease Drugs Revenue by Manufacturers
- 3.2.1 Chronic Obstructive Pulmonary Disease Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Chronic Obstructive Pulmonary Disease Drugs Revenue Share by Manufacturers (2014-2019)
- 3.3 Chronic Obstructive Pulmonary Disease Drugs Price by Manufacturers
- 3.4 Chronic Obstructive Pulmonary Disease Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Chronic Obstructive Pulmonary Disease Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Chronic Obstructive Pulmonary Disease Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Chronic Obstructive Pulmonary Disease Drugs Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Chronic Obstructive Pulmonary Disease Drugs Sales by Product
- 4.2 Global Chronic Obstructive Pulmonary Disease Drugs Revenue by Product
- 4.3 Chronic Obstructive Pulmonary Disease Drugs Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Chronic Obstructive Pulmonary Disease Drugs Breakdown Data by End User
6 North America
- 6.1 North America Chronic Obstructive Pulmonary Disease Drugs by Countries
- 6.1.1 North America Chronic Obstructive Pulmonary Disease Drugs Sales by Countries
- 6.1.2 North America Chronic Obstructive Pulmonary Disease Drugs Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Chronic Obstructive Pulmonary Disease Drugs by Product
- 6.3 North America Chronic Obstructive Pulmonary Disease Drugs by End User
7 Europe
- 7.1 Europe Chronic Obstructive Pulmonary Disease Drugs by Countries
- 7.1.1 Europe Chronic Obstructive Pulmonary Disease Drugs Sales by Countries
- 7.1.2 Europe Chronic Obstructive Pulmonary Disease Drugs Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Chronic Obstructive Pulmonary Disease Drugs by Product
- 7.3 Europe Chronic Obstructive Pulmonary Disease Drugs by End User
8 Asia Pacific
- 8.1 Asia Pacific Chronic Obstructive Pulmonary Disease Drugs by Countries
- 8.1.1 Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Sales by Countries
- 8.1.2 Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Chronic Obstructive Pulmonary Disease Drugs by Product
- 8.3 Asia Pacific Chronic Obstructive Pulmonary Disease Drugs by End User
9 Central & South America
- 9.1 Central & South America Chronic Obstructive Pulmonary Disease Drugs by Countries
- 9.1.1 Central & South America Chronic Obstructive Pulmonary Disease Drugs Sales by Countries
- 9.1.2 Central & South America Chronic Obstructive Pulmonary Disease Drugs Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Chronic Obstructive Pulmonary Disease Drugs by Product
- 9.3 Central & South America Chronic Obstructive Pulmonary Disease Drugs by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs by Countries
- 10.1.1 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Sales by Countries
- 10.1.2 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs by Product
- 10.3 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs by End User
11 Company Profiles
- 11.1 AstraZeneca
- 11.1.1 AstraZeneca Company Details
- 11.1.2 Company Business Overview
- 11.1.3 AstraZeneca Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 AstraZeneca Chronic Obstructive Pulmonary Disease Drugs Products Offered
- 11.1.5 AstraZeneca Recent Development
- 11.2 Boehringer Ingelheim
- 11.2.1 Boehringer Ingelheim Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Drugs Products Offered
- 11.2.5 Boehringer Ingelheim Recent Development
- 11.3 GSK
- 11.3.1 GSK Company Details
- 11.3.2 Company Business Overview
- 11.3.3 GSK Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 GSK Chronic Obstructive Pulmonary Disease Drugs Products Offered
- 11.3.5 GSK Recent Development
- 11.4 Novartis
- 11.4.1 Novartis Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Novartis Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Novartis Chronic Obstructive Pulmonary Disease Drugs Products Offered
- 11.4.5 Novartis Recent Development
- 11.5 Teva Pharmaceuticals
- 11.5.1 Teva Pharmaceuticals Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Products Offered
- 11.5.5 Teva Pharmaceuticals Recent Development
- 11.6 Ache Laboratorios Farmaceuticos
- 11.6.1 Ache Laboratorios Farmaceuticos Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Ache Laboratorios Farmaceuticos Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Ache Laboratorios Farmaceuticos Chronic Obstructive Pulmonary Disease Drugs Products Offered
- 11.6.5 Ache Laboratorios Farmaceuticos Recent Development
- 11.7 Almirall
- 11.7.1 Almirall Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Almirall Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Almirall Chronic Obstructive Pulmonary Disease Drugs Products Offered
- 11.7.5 Almirall Recent Development
- 11.8 Aquinox Pharmaceuticals
- 11.8.1 Aquinox Pharmaceuticals Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Products Offered
- 11.8.5 Aquinox Pharmaceuticals Recent Development
- 11.9 Ario Pharma
- 11.9.1 Ario Pharma Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Ario Pharma Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Ario Pharma Chronic Obstructive Pulmonary Disease Drugs Products Offered
- 11.9.5 Ario Pharma Recent Development
- 11.10 Asmacure
- 11.10.1 Asmacure Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Asmacure Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Asmacure Chronic Obstructive Pulmonary Disease Drugs Products Offered
- 11.10.5 Asmacure Recent Development
- 11.11 Astellas Pharma
- 11.12 BioMarck Pharmaceuticals
12 Future Forecast
- 12.1 Chronic Obstructive Pulmonary Disease Drugs Market Forecast by Regions
- 12.1.1 Global Chronic Obstructive Pulmonary Disease Drugs Sales Forecast by Regions 2019-2025
- 12.1.2 Global Chronic Obstructive Pulmonary Disease Drugs Revenue Forecast by Regions 2019-2025
- 12.2 Chronic Obstructive Pulmonary Disease Drugs Market Forecast by Product
- 12.2.1 Global Chronic Obstructive Pulmonary Disease Drugs Sales Forecast by Product 2019-2025
- 12.2.2 Global Chronic Obstructive Pulmonary Disease Drugs Revenue Forecast by Product 2019-2025
- 12.3 Chronic Obstructive Pulmonary Disease Drugs Market Forecast by End User
- 12.4 North America Chronic Obstructive Pulmonary Disease Drugs Forecast
- 12.5 Europe Chronic Obstructive Pulmonary Disease Drugs Forecast
- 12.6 Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Forecast
- 12.7 Central & South America Chronic Obstructive Pulmonary Disease Drugs Forecast
- 12.8 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Chronic Obstructive Pulmonary Disease Drugs Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Chronic Obstructive Pulmonary Disease Drugs . Industry analysis & Market Report on Chronic Obstructive Pulmonary Disease Drugs is a syndicated market report, published as Global Chronic Obstructive Pulmonary Disease Drugs Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Chronic Obstructive Pulmonary Disease Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
